Publications
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome2012 | First Faculty of Medicine
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient ?2011 | First Faculty of Medicine
- Does the development of new drugs for multiple sclerosis change the prognosis of the patient?2011 | First Faculty of Medicine
- Pharmacological treatment possibilities in clinically isolated syndrome2009 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | First Faculty of Medicine
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL2009 | First Faculty of Medicine
- Multiple sclerosis +112008 | First Faculty of Medicine
Loading network view...